163 related articles for article (PubMed ID: 23137818)
1. Ability of ELISA and a toxin neutralization assay to detect changes in immunogenicity of a recombinant Bacillus anthracis protective antigen vaccine upon storage.
DomÃnguez-Castillo RI; Verma A; Amador-Molina JC; Sirota L; Arciniega JL
Biologicals; 2013 Mar; 41(2):111-4. PubMed ID: 23137818
[TBL] [Abstract][Full Text] [Related]
2. Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines.
Parreiras PM; Sirota LA; Wagner LD; Menzies SL; Arciniega JL
Vaccine; 2009 Jul; 27(33):4537-42. PubMed ID: 19501205
[TBL] [Abstract][Full Text] [Related]
3. Structural and immunological analysis of anthrax recombinant protective antigen adsorbed to aluminum hydroxide adjuvant.
Wagner L; Verma A; Meade BD; Reiter K; Narum DL; Brady RA; Little SF; Burns DL
Clin Vaccine Immunol; 2012 Sep; 19(9):1465-73. PubMed ID: 22815152
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity in mice of anthrax recombinant protective antigen in the presence of aluminum adjuvants.
Berthold I; Pombo ML; Wagner L; Arciniega JL
Vaccine; 2005 Mar; 23(16):1993-9. PubMed ID: 15734073
[TBL] [Abstract][Full Text] [Related]
5. Immunization with a Recombinant, Pseudomonas fluorescens-Expressed, Mutant Form of Bacillus anthracis-Derived Protective Antigen Protects Rabbits from Anthrax Infection.
Reed MD; Wilder JA; Mega WM; Hutt JA; Kuehl PJ; Valderas MW; Chew LL; Liang BC; Squires CH
PLoS One; 2015; 10(7):e0130952. PubMed ID: 26207820
[TBL] [Abstract][Full Text] [Related]
6. Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine.
Little SF; Ivins BE; Webster WM; Norris SL; Andrews GP
Vaccine; 2007 Apr; 25(15):2771-7. PubMed ID: 17240008
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.
Gorse GJ; Keitel W; Keyserling H; Taylor DN; Lock M; Alves K; Kenner J; Deans L; Gurwith M
Vaccine; 2006 Aug; 24(33-34):5950-9. PubMed ID: 16797805
[TBL] [Abstract][Full Text] [Related]
8. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
Wimer-Mackin S; Hinchcliffe M; Petrie CR; Warwood SJ; Tino WT; Williams MS; Stenz JP; Cheff A; Richardson C
Vaccine; 2006 May; 24(18):3953-63. PubMed ID: 16530302
[TBL] [Abstract][Full Text] [Related]
9. Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization.
Li H; Soroka SD; Taylor TH; Stamey KL; Stinson KW; Freeman AE; Abramson DR; Desai R; Cronin LX; Oxford JW; Caba J; Pleatman C; Pathak S; Schmidt DS; Semenova VA; Martin SK; Wilkins PP; Quinn CP
J Immunol Methods; 2008 Apr; 333(1-2):89-106. PubMed ID: 18304568
[TBL] [Abstract][Full Text] [Related]
10. Protective antigen and extractable antigen 1 based chimeric protein confers protection against Bacillus anthracis in mouse model.
Makam SS; Kingston JJ; Harischandra MS; Batra HV
Mol Immunol; 2014 May; 59(1):91-9. PubMed ID: 24513572
[TBL] [Abstract][Full Text] [Related]
11. Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine.
Little SF; Ivins BE; Webster WM; Fellows PF; Pitt ML; Norris SL; Andrews GP
Vaccine; 2006 Mar; 24(14):2530-6. PubMed ID: 16417950
[TBL] [Abstract][Full Text] [Related]
12. S-layer homology motif is an immunogen and confers protection to mouse model against anthrax.
Kulshreshtha P; Aggarwal S; Jaiswal H; Bhatnagar R
Mol Immunol; 2012 Feb; 50(1-2):18-25. PubMed ID: 22178119
[TBL] [Abstract][Full Text] [Related]
13. Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.
Yan M; Roehrl MH; Basar E; Wang JY
Vaccine; 2008 Feb; 26(7):947-55. PubMed ID: 18192092
[TBL] [Abstract][Full Text] [Related]
14. Comparison of three anthrax toxin neutralization assays.
Ngundi MM; Meade BD; Lin TL; Tang WJ; Burns DL
Clin Vaccine Immunol; 2010 Jun; 17(6):895-903. PubMed ID: 20375243
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of an anthrax DNA vaccine with electroporation.
Luxembourg A; Hannaman D; Nolan E; Ellefsen B; Nakamura G; Chau L; Tellez O; Little S; Bernard R
Vaccine; 2008 Sep; 26(40):5216-22. PubMed ID: 18462850
[TBL] [Abstract][Full Text] [Related]
16. Mouse model characterisation for anthrax vaccine development: comparison of one inbred and one outbred mouse strain.
Flick-Smith HC; Waters EL; Walker NJ; Miller J; Stagg AJ; Green M; Williamson ED
Microb Pathog; 2005 Jan; 38(1):33-40. PubMed ID: 15652293
[TBL] [Abstract][Full Text] [Related]
17. [Immunogenicity of the recombinant Bacillus strains with cloned gene of biosynthesis of protective antigen against Bacillus anthracis].
Mikshis NI; Kudriavtseva OM; Bolothikova MF; Shulepov DV; Novikova LV; Popov IuA; Shchukovskaia TN; Drozdov IG; Kutyrev VV
Mol Gen Mikrobiol Virusol; 2007; (3):15-21. PubMed ID: 17886469
[TBL] [Abstract][Full Text] [Related]
18. Increased long-term immunity to Bacillus anthracis protective antigen in mice immunized with a CIA06B-adjuvanted anthrax vaccine.
Wui SR; Han JE; Kim YH; Rhie GE; Lee NG
Arch Pharm Res; 2013 Apr; 36(4):464-71. PubMed ID: 23440578
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults.
Brown BK; Cox J; Gillis A; VanCott TC; Marovich M; Milazzo M; Antonille TS; Wieczorek L; McKee KT; Metcalfe K; Mallory RM; Birx D; Polonis VR; Robb ML
PLoS One; 2010 Nov; 5(11):e13849. PubMed ID: 21079762
[TBL] [Abstract][Full Text] [Related]
20. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities.
Sloat BR; Cui Z
Pharm Res; 2006 Jun; 23(6):1217-26. PubMed ID: 16718616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
